이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Mind Medicine (MindMed) 관리

관리 기준 확인 4/4

Mind Medicine (MindMed)'s CEO는 Rob Barrow, Jun2021 에 임명되었습니다 의 임기는 2.5 년입니다. 총 연간 보상은 $ 2.14M, 27.9% 로 구성됩니다. 27.9% 급여 및 72.1% 보너스(회사 주식 및 옵션 포함). 는 $ 1.39M 가치에 해당하는 회사 주식의 0.26% 직접 소유합니다. 1.39M. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 2.8 년입니다.

주요 정보

Rob Barrow

최고 경영자

US$2.1m

총 보상

CEO 급여 비율	27.9%
CEO 임기	3.3yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

Psychedelic Stocks: Focus On Their Cash

Aug 15

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

Jun 05

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Apr 04

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Feb 02

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

May 23

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Feb 07

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Oct 19

MindMed announces proposed public offering of common shares

Sep 27

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Sep 20

MindMed regains compliance with Nasdaq's minimum bid price listing requirement

Sep 14

MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value

Sep 04

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Aug 26

Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder

Aug 24

MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps

Aug 18

CEO 보상 분석

Rob Barrow 의 보수는 Mind Medicine (MindMed) 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$102m
Mar 31 2024	n/a	n/a	-US$125m
Dec 31 2023	US$2m	US$599k	-US$96m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$63m
Dec 31 2022	US$5m	US$672k	-US$57m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$69m
Mar 31 2022	n/a	n/a	-US$98m
Dec 31 2021	US$12m	US$350k	-US$93m

보상 대 시장: Rob 의 총 보상 ($USD 2.14M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.41M ).

보상과 수익: Rob 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Rob Barrow (35 yo)

3.3yrs

테뉴어

US$2,143,133

보상

Mr. Robert Barrow, also known as Rob, serves as Chief Executive Officer at Mind Medicine (MindMed) Inc since June 9, 2021 and serves a its Director since December 13, 2021. He served as Chief Development O...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Barrow	CEO & Director	3.3yrs	US$2.14m	0.25% $ 1.1m
Daniel Karlin	Chief Medical Officer	3.7yrs	US$1.04m	0.29% $ 1.3m
Miriam Wernli	Executive President	4.2yrs	US$2.66m	0.14% $ 651.6k
Scott Freeman	Co-Founder & Clinical Advisor	no data	US$501.19k	데이터 없음
Leonard Latchman	Co-founder	no data	데이터 없음	데이터 없음
Carrie Liao	VP & Chief Accounting Officer	1.9yrs	데이터 없음	0.054% $ 246.6k
Mark Sullivan	Chief Legal Officer & Corporate Secretary	1.5yrs	데이터 없음	0.065% $ 293.6k
Francois Lilienthal	Chief Commercial Officer	2.5yrs	데이터 없음	데이터 없음
Stephanie Fagan	Chief Corporate Affairs Officer	less than a year	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

55.5yo

평균 연령

경험이 풍부한 관리: MNMD 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Barrow	CEO & Director	2.8yrs	US$2.14m	0.25% $ 1.1m
Carol Vallone	Independent Chairperson	3.1yrs	US$196.20k	0.016% $ 73.1k
David Gryska	Independent Director	1.3yrs	US$179.01k	0.010% $ 45.2k
Suzanne Bruhn	Independent Director	2.2yrs	US$148.70k	0.015% $ 68.2k
Robert Malenka	Chair of Scientific Advisory Board	3.6yrs	데이터 없음	데이터 없음
Robert Dworkin	Member of Scientific Advisory Board	3.2yrs	데이터 없음	데이터 없음
Maurizio Fava	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음
Andreas Krebs	Independent Vice Chairman	3.1yrs	US$186.20k	0.014% $ 65.1k
Roger Crystal	Independent Director	2.2yrs	US$148.70k	0.015% $ 68.2k
Peter Bergethon	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음
Maria Oquendo	Member of Scientific Advisory Board	2.9yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: MNMD 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Mind Medicine (MindMed) 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

CEO & Director notifies of intention to sell stock

Executive President exercised options and sold US$81k worth of stock

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Chief Financial Officer recently sold US$76k worth of stock

Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors

Recent updates

CEO & Director notifies of intention to sell stock

Price target increased by 9.3% to US$26.50

Executive President exercised options and sold US$81k worth of stock

Mind Medicine (Mindmed) Inc. Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) At American Psychiatric Association

Psychedelic Stocks: Focus On Their Cash

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $74.998573 million.

Mind Medicine (MindMed) Inc. has filed a Follow-on Equity Offering.

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Mind Medicine (MindMed) Inc.(NasdaqGS:MNMD) dropped from Russell 3000E Value Index

Mind Medicine (MindMed) Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder

New major risk - Shareholder dilution

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Price target increased by 10% to US$28.67

Mind Medicine (MindMed) Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Price target increased by 7.5% to US$26.17

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Mind Medicine (Mindmed) Inc. Provides Anticipated Production Milestones for 2024

Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

New minor risk - Share price stability

Price target increased by 14% to US$25.83

Price target decreased by 36% to US$14.50

New major risk - Revenue and earnings growth

Price target increased by 14% to US$25.83

New minor risk - Market cap size

Mind Medicine (MindMed) Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Mind Medicine Completes Enrollment and Dosing in Study Mmed008

Chief Financial Officer recently sold US$76k worth of stock

New minor risk - Share price stability

Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors

FCM MM Holdings Posts Material on Social Media Platforms

FCM MM Holdings Calls for Socially Responsible Investors to Vote for Change at Mind Medicine

FCM MM Holdings Posts Material on Twitter

FCM MM Holdings Provides Information to Shareholders of Mind Medicine

FCM MM Holdings Condemns the Report Issued by Institutional Shareholder Services

FCM MM Holdings LLC Issues a Letter to the Shareholders of Mind Medicine Inc

FCM MM Holdings Posts Materials to Reddit

FCM MM Holdings Sends Letter to Shareholders of Mind Medicine (MindMed)

Mind Medicine Posts Materials to Twitter

FCM MM Holdings Issues an Investor Presentation to Shareholders of Mind Medicine

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Mind Medicine (MindMed) Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD

FCM Director Nominees Will Put MindMed Drug Development Process Back on Track

Mind Medicine Launches a Website and Post the Materials

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 15, 2023

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Price target decreased by 11% to US$27.63

High number of new and inexperienced directors

FCM MM Holdings LLC Sends a Letter to Mind Medicine (MindMed) Inc

FCM MM HOLDINGS, LLC Demands Federal Investigation to Probe Serious Allegations of Misconduct at Mind Medicine (MindMed) Inc

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Mind Medicine Announces Initiation of Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

FCM MM HOLDINGS Sends Letter to the Board of Mind Medicine

MindMed announces proposed public offering of common shares

Mind Medicine (MindMed) Inc. Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Price target decreased to US$51.10

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Mind Medicine Regains Compliance with Nasdaq's Minimum Bid Price Listing Requirement

MindMed regains compliance with Nasdaq's minimum bid price listing requirement

Mind Medicine (MindMed) Inc. Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value

Mind Medicine (MindMed) Inc. Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans